Tumor Treating Fields may disrupt tumor communication and induce conditional BRCAness in malignant pleural mesothelioma
New review explains how Tumor Treating Fields disrupts cancer cell networks in mesothelioma
This review explores the theoretical mechanisms of Tumor Treating Fields (TTFields) in malignant pleural mesothelioma. The authors describe …
A new review explains how Tumor Treating Fields disrupts cancer cell networks and changes the immune environment in malignant pleural mesoth…
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data
Your Lung Cancer Drug May Have Side Effects Not on the Label
This pharmacovigilance study analyzed 27,098 pemetrexed-associated reports in the US FAERS database from 2004 to 2024.
A safety review of over 27,000 reports found that the lung cancer drug pemetrexed may cause side effects not currently listed on its officia…
Nivolumab+ipilimumab shows 5-year OS benefit (14% vs 6%) vs chemo in unresectable pleural mesothelioma
Can immunotherapy help people with advanced mesothelioma live longer? Five-year results show it can
In the 5-year follow-up of CheckMate 743, nivolumab plus ipilimumab demonstrated continued overall survival benefit versus chemotherapy in u…
Five years after starting treatment, 14% of advanced mesothelioma patients survived on immunotherapy versus 6% on chemotherapy, proving last…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…
Research across Cancer
Related studies from across the Cancer family.
